About VANTAS VANTAS(R) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. VANTAS is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any components in VANTAS.
About SUPPRELIN LA
SUPPRELIN(R) LA is a subcutaneous implant indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. It utilizes the hydron implant technology and is specifically designed to provide a continuous release over 12 months of the gonadotropin releasing hormone (GnRH) agonist, histrelin. SUPPRELIN LA is contraindicated in patients with hypersensitivity to GnRH or GnRH analogs.
Forward Looking Statements
Except for the descriptions of historical facts contained herein, this
press release contains forward-looking statements that involve risks and
uncertainties that could cause the Company's actual results and financial
condition to differ materially from those anticipated by the forward-looking
statements. These risks and uncertainties are set forth in the Company's
filings under the Securities Act of 1933 and the Securities Exchange Act of
1934 under "Risk Factors" and elsewhere, and include, but are not limited to:
dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) ,
VANTAS(R) and SUPPRELIN(R) LA; need for additional funds and corporate
partners, including for the development of our products; effectiveness of our
sales force; competition and its effect on pricing, spending, third-party
relationships and revenues; dependence on third parties for supplies,
particularly for histrelin, manufacturing, marketing, and clinical trials;
risks associated wit
|SOURCE Indevus Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved